Phreesia, Inc. (NYSE:PHR) Receives $29.33 Average PT from Brokerages

Shares of Phreesia, Inc. (NYSE:PHR) have been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $29.33.

Several research firms recently weighed in on PHR. Robert W. Baird dropped their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Truist Financial boosted their price objective on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. raised their target price on shares of Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Monday, September 9th. Finally, DA Davidson reaffirmed a “buy” rating and issued a $32.00 price target on shares of Phreesia in a report on Thursday, September 5th.

Phreesia Trading Down 0.7 %

Shares of PHR stock opened at $25.19 on Friday. Phreesia has a twelve month low of $17.07 and a twelve month high of $29.16. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. The business’s 50 day moving average is $20.90 and its two-hundred day moving average is $22.04. The company has a market capitalization of $1.46 billion, a P/E ratio of -17.14 and a beta of 0.98.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm’s revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.58) earnings per share. Equities analysts forecast that Phreesia will post -1.16 EPS for the current year.

Insider Activity at Phreesia

In related news, insider Yvonne Hui sold 2,791 shares of Phreesia stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.92, for a total value of $58,387.72. Following the transaction, the insider now owns 27,228 shares in the company, valued at approximately $569,609.76. This trade represents a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael Weintraub sold 20,565 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $25.04, for a total value of $514,947.60. Following the sale, the director now directly owns 242,827 shares of the company’s stock, valued at approximately $6,080,388.08. This trade represents a 7.81 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,342 shares of company stock worth $2,041,225. 5.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Phreesia

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its holdings in Phreesia by 8.4% in the second quarter. Bank of New York Mellon Corp now owns 214,430 shares of the company’s stock valued at $4,546,000 after buying an additional 16,614 shares during the period. Peregrine Capital Management LLC grew its position in Phreesia by 11.3% in the second quarter. Peregrine Capital Management LLC now owns 354,607 shares of the company’s stock valued at $7,518,000 after acquiring an additional 36,047 shares in the last quarter. nVerses Capital LLC raised its stake in shares of Phreesia by 76.5% during the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after purchasing an additional 1,300 shares during the period. Rhumbline Advisers lifted its position in shares of Phreesia by 1.0% during the second quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock worth $1,741,000 after purchasing an additional 853 shares in the last quarter. Finally, Arcadia Investment Management Corp MI boosted its stake in shares of Phreesia by 13.9% in the second quarter. Arcadia Investment Management Corp MI now owns 88,625 shares of the company’s stock valued at $1,879,000 after purchasing an additional 10,800 shares during the period. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.